Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)

NCT01073163 is registered in ClinicalTrials.gov with Cephalon as lead sponsor.

NCT NCT01073163
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01073163 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)
Lead sponsor
Cephalon
Phase
Phase 3
Overall status
Completed
Start date
February 28, 2010
Completion date
June 30, 2012
Enrollment
54 (actual)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

mantle cell lymphoma, non-hodgkin's lymphoma